{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:41:22Z","timestamp":1778877682488,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"crossref","award":["CER-1602-34473"],"award-info":[{"award-number":["CER-1602-34473"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-025-00674-0","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T15:03:16Z","timestamp":1763823796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of second intravenous immunoglobulin infusion versus infliximab for treating IVIG-resistant Kawasaki disease patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Jada M.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kit N.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie N.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana H.","family":"Tremoulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane C.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"3","key":"674_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1542\/peds.54.3.271","volume":"54","author":"T Kawasaki","year":"1974","unstructured":"Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54(3):271\u20136.","journal-title":"Pediatrics"},{"issue":"6","key":"674_CR2","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0022-3476(75)80220-4","volume":"86","author":"H Kato","year":"1975","unstructured":"Kato H, Koike S, Yamamoto M, Ito Y, Yano E. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J Pediatr. 1975;86(6):892\u20138.","journal-title":"J Pediatr"},{"issue":"17","key":"674_CR3","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term management of Kawasaki disease: A scientific statement for health professionals from the American heart association. Circulation. 2017;135(17):e927\u201399.","journal-title":"Circulation"},{"key":"674_CR4","doi-asserted-by":"crossref","unstructured":"Skochko SM, Jain S, Sun X, Sivilay N, Kanegaye JT, Pancheri J et al. Kawasaki disease outcomes and response to therapy in a multiethnic community: a 10-Year experience. J Pediatr. 2018;203:408\u201315 e3.","DOI":"10.1016\/j.jpeds.2018.07.090"},{"issue":"9","key":"674_CR5","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/00006454-200009000-00004","volume":"19","author":"ED Belay","year":"2000","unstructured":"Belay ED, Holman RC, Clarke MJ, Destefano F, Shahriari A, Davis RL, et al. The incidence of Kawasaki syndrome in West Coast health maintenance organizations. Pediatr Infect Dis J. 2000;19(9):828\u201332.","journal-title":"Pediatr Infect Dis J"},{"key":"674_CR6","doi-asserted-by":"crossref","unstructured":"Ae R, Makino N, Kosami K, Kuwabara M, Matsubara Y, Nakamura Y. Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: the nationwide survey in Japan, 2017\u20132018. J Pediatr. 2020;225:23\u20139 e2.","DOI":"10.1016\/j.jpeds.2020.05.034"},{"issue":"2","key":"674_CR7","doi-asserted-by":"publisher","first-page":"E27","DOI":"10.1542\/peds.106.2.e27","volume":"106","author":"JC Burns","year":"2000","unstructured":"Burns JC, Kushner HI, Bastian JF, Shike H, Shimizu C, Matsubara T, et al. Kawasaki disease: A brief history. Pediatrics. 2000;106(2):E27.","journal-title":"Pediatrics"},{"issue":"2","key":"674_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2188\/jea.JE20110131","volume":"22","author":"R Uehara","year":"2012","unstructured":"Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the united States. J Epidemiol. 2012;22(2):79\u201385.","journal-title":"J Epidemiol"},{"issue":"2","key":"674_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s12098-015-1890-4","volume":"83","author":"S Singh","year":"2016","unstructured":"Singh S, Sharma A, Jiao F. Kawasaki disease: issues in diagnosis and Treatment\u2013A developing country perspective. Indian J Pediatr. 2016;83(2):140\u20135.","journal-title":"Indian J Pediatr"},{"issue":"5","key":"674_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpeds.2004.12.022","volume":"146","author":"JC Burns","year":"2005","unstructured":"Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146(5):662\u20137.","journal-title":"J Pediatr"},{"issue":"6","key":"674_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJM198608073150601","volume":"315","author":"JW Newburger","year":"1986","unstructured":"Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma Globulin. N Engl J Med. 1986;315(6):341\u20137.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"674_CR12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cei.12546","volume":"178","author":"A Sediva","year":"2014","unstructured":"Sediva A, Chapel H, Gardulf A. European Immunoglobulin map group for European society for immunodeficiencies primary immunodeficiencies care in development working P. Europe Immunoglobulin map. Clin Exp Immunol. 2014;178(Suppl 1):141\u20133.","journal-title":"Clin Exp Immunol"},{"key":"674_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ijcard.2016.03.017","volume":"214","author":"T Kibata","year":"2016","unstructured":"Kibata T, Suzuki Y, Hasegawa S, Matsushige T, Kusuda T, Hoshide M, et al. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial Immunoglobulin. Int J Cardiol. 2016;214:209\u201315.","journal-title":"Int J Cardiol"},{"issue":"1","key":"674_CR14","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41598-017-18387-7","volume":"8","author":"M Mori","year":"2018","unstructured":"Mori M, Hara T, Kikuchi M, Shimizu H, Miyamoto T, Iwashima S, et al. Infliximab versus intravenous Immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Sci Rep. 2018;8(1):1994.","journal-title":"Sci Rep"},{"issue":"12","key":"674_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S2352-4642(21)00270-4","volume":"5","author":"JC Burns","year":"2021","unstructured":"Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, et al. Infliximab versus second intravenous Immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health. 2021;5(12):852\u201361.","journal-title":"Lancet Child Adolesc Health"},{"issue":"9826","key":"674_CR16","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(11)61930-2","volume":"379","author":"T Kobayashi","year":"2012","unstructured":"Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of Immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613\u201320.","journal-title":"Lancet"},{"issue":"2","key":"674_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jjcc.2022.03.005","volume":"80","author":"T Takura","year":"2022","unstructured":"Takura T, Horiuchi S. Cost-effectiveness analysis of Infliximab for the treatment of Kawasaki disease refractory to the initial treatment: A retrospective cohort study. J Cardiol. 2022;80(2):172\u20138.","journal-title":"J Cardiol"},{"issue":"1","key":"674_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1542\/hpeds.2020-0188","volume":"11","author":"SC Johnson","year":"2021","unstructured":"Johnson SC, Williams DC, Brinton D, Chew M, Simpson A, Andrews AL. A cost comparison of Infliximab versus intravenous Immunoglobulin for refractory Kawasaki disease treatment. Hosp Pediatr. 2021;11(1):88\u201393.","journal-title":"Hosp Pediatr"},{"issue":"1","key":"674_CR19","first-page":"64","volume":"5","author":"FA Mir","year":"2018","unstructured":"Mir FA, Juboori AA, Bragg JD, Tahan V. Autoimmune hemolytic anemia associated with Infliximab infusion in ulcerative colitis. North Clin Istanb. 2018;5(1):64\u20136.","journal-title":"North Clin Istanb"},{"key":"674_CR20","unstructured":"Centers for Disease Control and Prevention National Center for Health Statistics. Clinical Growth Charts. [Available from: https:\/\/www.cdc.gov\/growthcharts\/clinical_charts.htm"},{"key":"674_CR21","unstructured":"US Department of Labor Bureau of Labor Statistics. May 2021 National Occupational Employment and Wage Estimates United States. [Internet]. [cited January 3, 2023]. Available from: https:\/\/www.bls.gov\/oes\/tables.htm"},{"key":"674_CR22","unstructured":"US Department of Labor Bureau of Labor Statistics. Consumer Price Index (CPI) Databases [Internet]. [cited December 13, 2022]. Available from: https:\/\/www.bls.gov\/cpi\/data.htm"},{"issue":"1","key":"674_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13063-022-07051-9","volume":"24","author":"D Eleftheriou","year":"2023","unstructured":"Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, et al. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous Immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol. Trials. 2023;24(1):60.","journal-title":"Trials"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00674-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00674-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00674-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:41:22Z","timestamp":1767033682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-025-00674-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00674-0","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}